The Most Common Blood Protein May Control How Cannabinoid Drugs Work in Your Body
Computational modeling showed that human serum albumin, the most abundant blood protein, avidly binds multiple cannabinoid drugs, potentially acting as a key determinant of their effectiveness and dosing.
Quick Facts
What This Study Found
This study investigated whether human serum albumin (HSA), the most abundant protein in blood plasma, serves as a major transporter for cannabinoid drugs.
Using computational docking methods, the researchers found that HSA binds strongly to a wide range of cannabinoid compounds: indirect agonists (URB597, AM5206, JZL184, JZL195, AM404), direct agonists (WIN55,212-2, CP55,940), and the antagonist/inverse agonist SR141716 (rimonabant).
Binding energies ranged from -5.4 to -10.9 kcal/mol. Given the high concentration of HSA in blood (~750 micromolar), the modeling suggests these complexes would form readily under physiological conditions.
Since HSA already binds the natural endocannabinoid anandamide and THC, it appears to be a universal carrier for cannabinoid compounds. This has practical implications: the amount of HSA in a patient's blood could significantly affect how much "free" (active) cannabinoid drug is available to produce effects.
Key Numbers
Binding energies: -5.4 to -10.9 kcal/mol across 8 cannabinoid drugs. HSA blood concentration: ~750 micromolar. THC and anandamide are already known to bind HSA.
How They Did This
In silico molecular docking study using computational methods to model the binding interactions between HSA and eight different cannabinoid drugs. Free energy calculations estimated binding strength. Results were contextualized against known HSA concentration in human blood.
Why This Research Matters
If HSA is a major determinant of cannabinoid drug levels in the blood, it could explain why cannabis and cannabinoid drugs affect people differently. Patients with lower albumin levels (liver disease, malnutrition, elderly) might experience stronger effects from the same dose, while those with higher albumin might need more.
The Bigger Picture
Drug-protein binding is a fundamental concept in pharmacology that has been largely unexplored for cannabinoids. If HSA binding significantly affects cannabinoid bioavailability, it could influence dosing guidelines, explain individual variation in response, and become a factor in drug interaction predictions.
What This Study Doesn't Tell Us
Computational (in silico) modeling only, without experimental confirmation of binding affinities or biological relevance. Docking scores do not always accurately predict real binding behavior. The study does not address whether HSA binding changes cannabinoid drug activity in living systems.
Questions This Raises
- ?Do patients with low albumin (liver disease, malnutrition) experience stronger cannabis effects?
- ?Could HSA binding explain some drug interactions between cannabinoids and other highly protein-bound drugs?
- ?Would measuring albumin levels help personalize cannabinoid dosing?
Trust & Context
- Key Stat:
- HSA binds cannabinoid drugs with energies of -5.4 to -10.9 kcal/mol at blood concentrations of 750 micromolar
- Evidence Grade:
- Computational modeling study without experimental validation. Preliminary but raises important pharmacokinetic questions.
- Study Age:
- Published in 2017.
- Original Title:
- Human serum albumin: A modulator of cannabinoid drugs.
- Published In:
- IUBMB life, 69(11), 834-840 (2017)
- Authors:
- Leboffe, Loris, di Masi, Alessandra, Trezza, Viviana(4), Polticelli, Fabio, Ascenzi, Paolo
- Database ID:
- RTHC-01432
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do people respond differently to the same cannabis dose?
This study suggests one factor may be how much albumin (a blood protein) they have. HSA binds cannabinoids tightly, so patients with different albumin levels would have different amounts of "free" active drug in their blood from the same dose.
What is human serum albumin?
It is the most abundant protein in blood plasma, responsible for transporting many drugs and molecules through the body. This study found it also binds strongly to cannabinoid drugs, potentially affecting their distribution and effectiveness.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01432APA
Leboffe, Loris; di Masi, Alessandra; Trezza, Viviana; Polticelli, Fabio; Ascenzi, Paolo. (2017). Human serum albumin: A modulator of cannabinoid drugs.. IUBMB life, 69(11), 834-840. https://doi.org/10.1002/iub.1682
MLA
Leboffe, Loris, et al. "Human serum albumin: A modulator of cannabinoid drugs.." IUBMB life, 2017. https://doi.org/10.1002/iub.1682
RethinkTHC
RethinkTHC Research Database. "Human serum albumin: A modulator of cannabinoid drugs." RTHC-01432. Retrieved from https://rethinkthc.com/research/leboffe-2017-human-serum-albumin-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.